CTMX
$5.34
Cytomx Thera
$.23
4.50%
CTMX
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.30)
Revenue:  $17.41 Mil
Thursday
Nov 4
4:15 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CTMX reports earnings?
Beat
Meet
Miss

Where is CTMX's stock price going from here?
Up
Flat
Down
Stock chart of CTMX
Analysts
Summary of analysts' recommendations for CTMX
Score
Grade
Pivots
Resistance
$5.91
$5.63
$5.49

$5.21

Support
$5.07
$4.79
$4.65
Tweet
Growth
Description
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.